Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Yf-H-2015005, a New CXCR4 Antagonist, in the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma: A Randomized-Controlled Phase 3 Study

Blood (2019) 134 (Supplement_1): 590.

https://doi.org/10.1182/blood-2019-125456

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

Bone Marrow Involvement in Primary Mediastinal B-Cell Large-Cell Lymphoma

Ekaterina Alexsandrovna Fastova, Aminat U. Magomedova, MD PhD, Alla M. Kovrigina, MD PhD, Yana K. Mangasarova, MD PhD, Sergey K. Kravchenko, MD PhD, Valeriy G. Savchenko, Andrey I. Vorobiev

Blood (2017) 130 (Supplement 1): 5239.

https://doi.org/10.1182/blood.V130.Suppl_1.5239.5239

Published: 2017

Journal Articles

Epidemiological Approach of Chronic Myeloid Leukemia. Algerian-Tunisian Study

Blood (2016) 128 (22): 5440.

https://doi.org/10.1182/blood.V128.22.5440.5440

Published: 2016

Journal Articles

Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma

Jacob D Soumerai, MD, Andrew D Zelenetz, MD PhD, Craig H Moskowitz, MD, Anas Younes, MD, Maria Lia Palomba, MD, Paul A Hamlin, Jr., MD, Ariela Noy, MD, Steven M Horwitz, MD, Matthew J. Matasar, MD MS, Alison J Moskowitz, MD, Carol S Portlock, MD, David J Straus, MD, Alice Chen, MD, Richard F Little, MDMPH, Fallon France, Juho Whang, Nishant Mishra, Christine Jarjies, John F Gerecitano, MD PhD

Blood (2015) 126 (23): 2691.

https://doi.org/10.1182/blood.V126.23.2691.2691

Published: 2015

Journal Articles

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

Charles L. Bennett, MD PhD, Sony Jacob, MD, Peter Georgantopoulos, MPH, MA, Judy Nichols, MSN, ACNP, Iain C Macdougall, MD

Blood (2014) 124 (21): 3516.

https://doi.org/10.1182/blood.V124.21.3516.3516

Published: 2014

Journal Articles

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Simon Durrant, MD, Maya Koren-Michowitz, MD, David Lavie, Joaquin Martinez-Lopez, MD PhD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Dana Iommazzo, Prashanth Gopalakrishna, MBBS, MRCS, Heinz Gisslinger, MD

Blood (2014) 124 (21): 710.

https://doi.org/10.1182/blood.V124.21.710.710

Published: 2014

Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB

Blood (2013) 122 (21): 5612.

https://doi.org/10.1182/blood.V122.21.5612.5612

Published: 2013

Journal Articles

Characteristics Associated With Transfusion Reaction Alerts At An Academic Medical Center

John Clark Henegan, MD, Mohamed Ayman Asfour, MD

Blood (2013) 122 (21): 4831.

https://doi.org/10.1182/blood.V122.21.4831.4831

Published: 2013

Journal Articles

ABT-888 Plus Bendamustine Is Safe and Has Shown Preliminary Efficacy In Patients With Lymphoma

Blood (2013) 122 (21): 4366.

https://doi.org/10.1182/blood.V122.21.4366.4366

Published: 2013

Journal Articles

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease

Blood (2013) 122 (21): 505.

https://doi.org/10.1182/blood.V122.21.505.505

Published: 2013

Journal Articles

Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial

Martha L Louzada, BSc, MD, MSc, Cyrus C. Hsia, BSc, MD, FRCPC, Fiona Ralley, MB ChB FRCA, Janet Martin, PharmD, MSc (HTA&M), Sarah Connelly, BSc MSc, Donna Berta, RN, Valerie Binns, RN, George D Ormond, BSc, Ian H. Chin-Yee, MD, FRCPC

Blood (2011) 118 (21): 2107.

https://doi.org/10.1182/blood.V118.21.2107.2107

Published: 2011

Journal Articles

Descriptive Study: sleep disorders breathing and Polysomnographic changes in Children and Adolescents with Sickle Cell Disease

Celia M. Campanaro, MD, Jose Carlos Pereira, Jr., MD, Jose Hugo Lins Pessoa, MD, Marcia Pradella Halimann, MD, Monica Favoreto, MD

Blood (2011) 118 (21): 4849.

https://doi.org/10.1182/blood.V118.21.4849.4849

Published: 2011

Journal Articles

Rituximab, Endoxan, Ganciclovir, Dexamethasone, Tocilizumab Sequential Treatment In Kaposi's Sarcoma-Associated Herpesvirus (KSHV) -Related Multicentric Castleman Disease. A Case Report with 8 Months Follow-up

Francesco Iuliano, Tecla Mingrone, Stefania Infusino, Alessia Perricelli, Angelo Pomillo, Maria Luci, Massimo Di Maio

Blood (2010) 116 (21): 4872.

https://doi.org/10.1182/blood.V116.21.4872.4872

Published: 2010

Journal Articles

Successful Hematopoietic STEM CELL Mobilization with GRANULOCYTE Colony Stimulating FACTOR PLUS Plerixafor (MOZOBIL, AMD3100) IN POOR Mobilizers: A Single CENTER STUDY

Despina Mallouri, Ioanna Sakellari, Chrisa Apostolou, Panayotis Baliakas, Apostolia Papalexandri, Aliki Tsobanakou, Ioannis Batsis, Evangelia Yannaki, Christos Smias, Damianos Sotiropoulos, Athanasios Fassas, Achilles Anagnostopoulos

Blood (2010) 116 (21): 4444.

https://doi.org/10.1182/blood.V116.21.4444.4444

Published: 2010

Journal Articles

Clinical Presentation, Treatment and Outcome of HIV-Associated Multicentric Castleman Disease

Musa Alzahrani, MD, Mark C Hull, MD, Christopher Sherlock, MD, Deborah Griswold, MD, Chantal S Leger, MD, Shannon Jackson, MD, Christopher P Venner, BSc, MD, Tyler W Smith, MD, Heather A Leitch, MD, PhD

Blood (2010) 116 (21): 3897.

https://doi.org/10.1182/blood.V116.21.3897.3897

Published: 2010

Journal Articles

TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial.

David T. Chung, Li-Wen Chang, Ying-Huey Huang, Cheng-Yuan Tsai, Ching-Hung Hsu, Chi-Hsin R. King, Judy H. Yuan, Chi-Feng Yen, Yu-Mai Chen, Yi Chin Lu, Ming-Chu Hsu, PhD

Blood (2009) 114 (22): 866.

https://doi.org/10.1182/blood.V114.22.866.866

Published: 2009

Journal Articles

A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF).

Srdan Verstovsek, MD, Azra Raza, MD, Aaron D. Schimmer, MD, Jean Viallet, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 3553.

https://doi.org/10.1182/blood.V110.11.3553.3553

Published: 2007

Journal Articles

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

Bertrand Coiffier, H. Tilly, L. M. Pedersen, T. Plesner, H. Frederiksen, M.H.J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. J. Walewski, M.F. Flensburg, J. Petersen, T. Robak

Blood (2005) 106 (11): 448.

https://doi.org/10.1182/blood.V106.11.448.448

Published: 2005

NARROW

Yf-H-2015005, a New CXCR4 Antagonist, in the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma: A Randomized-Controlled Phase 3 Study

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Bone Marrow Involvement in Primary Mediastinal B-Cell Large-Cell Lymphoma

Epidemiological Approach of Chronic Myeloid Leukemia. Algerian-Tunisian Study

Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Characteristics Associated With Transfusion Reaction Alerts At An Academic Medical Center

ABT-888 Plus Bendamustine Is Safe and Has Shown Preliminary Efficacy In Patients With Lymphoma

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease

Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial

Descriptive Study: sleep disorders breathing and Polysomnographic changes in Children and Adolescents with Sickle Cell Disease

Rituximab, Endoxan, Ganciclovir, Dexamethasone, Tocilizumab Sequential Treatment In Kaposi's Sarcoma-Associated Herpesvirus (KSHV) -Related Multicentric Castleman Disease. A Case Report with 8 Months Follow-up

Successful Hematopoietic STEM CELL Mobilization with GRANULOCYTE Colony Stimulating FACTOR PLUS Plerixafor (MOZOBIL, AMD3100) IN POOR Mobilizers: A Single CENTER STUDY

Clinical Presentation, Treatment and Outcome of HIV-Associated Multicentric Castleman Disease

TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial.

A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF).

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only